Treatment of patients with COPD and recurrent exacerbations: The role of infection and inflammation

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 515-525

  Santos, Salud ^a,b   Marin, Alicia ^b,c   Serra Batlles, Joan ^d   de la Rosa, David ^e   Solanes, Ingrid ^f   Pomares, Xavier ^g   López Sánchez, Marta ^a   Muñoz Esquerre, Mariana ^a   Miravitlles, Marc ^b,h  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d Hospital Universitari de Vic   (Spain)

^e HOSPITAL PLATÓ   (Spain)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g Parc Taulí Hospital Universitari   (Spain)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Anti inflammatory treatment; Antibiotics; Bronchial infection; COPD exacerbation; Treatment

Indexed keywords

AZITHROMYCIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; ERYTHROMYCIN; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; LEUKOTRIENE B4; LEUKOTRIENE D4; LONG ACTING DRUG; MOXIFLOXACIN; PLACEBO; REACTIVE OXYGEN METABOLITE; ROFLUMILAST; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; DRUG EFFICACY; ENTEROBACTERIACEAE; FORCED EXPIRATORY VOLUME; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFLUENZA VIRUS; LIVER FUNCTION; LUNG FUNCTION; LUNG INFECTION; MORAXELLA CATARRHALIS; PARAMYXOVIRINAE; PNEUMONIA; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; RHINOVIRUS; STENOTROPHOMONAS; STREPTOCOCCUS PNEUMONIAE; BACTERIAL INFECTIONS; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); COMPLICATION; DISEASE COURSE; DISEASE MANAGEMENT; IMMUNOLOGY; INFLAMMATION; MICROBIOLOGY; PATHOPHYSIOLOGY; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENT DISEASE; RISK FACTOR; SECONDARY PREVENTION; SEVERITY OF ILLNESS INDEX; VIRUS DISEASES;

BACTERIAL INFECTIONS; CLINICAL DECISION-MAKING; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; DISEASE PROGRESSION; HUMANS; INFLAMMATION; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SECONDARY PREVENTION; SEVERITY OF ILLNESS INDEX; SYMPTOM FLARE UP; VIRUS DISEASES;

EID: 84961241360     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S98333     Document Type: Article

References (66)

1. Hurst JR, Vestbo J, Anzueto A, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128-1138.
2. Miravitlles M, Calle M, Soler-Cataluna JJ. Clinical phenotypes of COPD. Identification, definition and implications for guidelines. Arch Bronconeumol. 2012;48:86-98.
3. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012;379:1341-1351.
4. Garcha DS, Thurston SJ, Patel AR, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax. 2012;67:1075-1080.
5. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184:662-671.
6. Miravitlles M, Espinosa C, Fernandez-Laso E, et al; Study Group of Bacterial Infection in COPD. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999;116:40-46.
7. George SN, Garcha DS, Mackay AJ, et al. Human rhinovirus infection during naturally occurring COPD exacerbations. Eur Respir J. 2014; 44:87-96.
8. Mallia P, Message SD, Gielen V, et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med. 2011;183:734-742.
9. Molyneaux PL, Mallia P, Cox MJ, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188: 1224-1231.
10. Matkovic Z, Miravitlles M. Chronic bronchial infection in COPD. Is there an infective phenotype? Respir Med. 2013;107:10-22.
11. Martinez-Garcia MA, Soler-Cataluna JJ, Donat Sanz Y, et al. Factors associated with bronchiectasis in chronic obstructive pulmonary disease patients. Chest. 2011;140:1130-1137.
12. Miravitlles M, Anzueto A. Antibiotic prophylaxis in COPD: why, when, and for whom? Pulm Pharmacol Ther. 2015;32:119-123.
13. Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease. Eur Respir J. 2013;42:239-251.
14. Albert RK, Connett J, Bailey WC, et al; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689-698.
15. Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithro-mycin therapy. Am JRespir Crit Care Med. 2014;189:1503-1508.
16. Uzun S, Djamin RS, Kluytmans JA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2:361-368.
17. Sethi S, Jones PW, Theron MS, et al; PULSE Study Group. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010;11:10.
18. Miravitlles M, Soler-Cataluna JJ, Calle M, et al; Spanish Society of Pul-monology and Thoracic Surgery. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch Bronconeumol. 2012;48:247-257.
19. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187: 347-365.
20. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003; 22:672-688.
21. Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet. 2004;364:985-996.
22. Rutgers SR, Postma DS, ten Hacken NH, et al. Ongoing airway inflam-mation in patients with COPD who do not currently smoke. Thorax. 2000;55:12-18.
23. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350: 2645-2653.
24. Stanescu D, Sanna A, Veriter C, et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax. 1996;51:267-271.
25. Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with chronic fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167:418-424.
26. Barrecheguren M, Esquinas C, Miravitlles M. The asthma COPD overlap syndrome (ACOS). Opportunities and challenges. Curr Opin Pulm Med. 2015;21:74-79.
27. Soler-Cataluna JJ, Cosio B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol. 2012;48:331-337.
28. Christenson SA, Steiling K, van den Berge M, et al. Asthma-COPD overlap: clinical relevance of genomic signatures of Type 2 inflammation in COPD. Am J Respir Crit Care Med. 2015;191:758-766.
29. Miravitlles M, Soriano JB, Ancochea J, et al. Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status. Respir Med. 2013;107:1053-1060.
30. Barrecheguren M, Roman-Rodriguez M, Miravitlles M. Is a previous diagnosis of asthma a reliable criterion for asthma-COPD overlap syn-drome (ACOS) in a patient with COPD? Int J Chron Obstruct Pulmon Dis. 2015;10:1745-1752.
31. Calverley PM, Anderson JA, Celli B, et al; TORCH Investigators. Sal- meterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789.
32. Alcazar Navarrete B, Casanova C, Miravitlles M, et al; Documento de consenso sobre el uso adecuado de los corticoides inhalados en la EPOC Study Group. Correct use of inhaled corticosteroids in chronic obstructive pulmonary disease: a consensus document. Arch Bronconeumol. 2015;51:193-198.
33. Leigh R, Pizzichini MM, Morris MM, et al. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J. 2006;27:964-971.
34. Kitaguchi Y, Komatsu Y, Fujimoto K, et al. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis. 2012;7:283-289.
35. van der Valk P, Monninkhof E, van der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med. 2002;166:1358-1363.
36. Magnussen H, Disse B, Rodriguez-Roisin R, et al; WISDOM Inves-tigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285-1294.
37. Martinez FJ, Calverley PM, Goehring UM, et al. Effect of roflumilast on exacerbations in patients with severe chronic pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomized controlled trial. Lancet. 2015;385:857-866.
38. Munoz-Esquerre M, Diez-Ferrer M, Monton C, et al. Roflumilast added to triple therapy in patients with severe COPD: a real life study. Pulm Pharmacol Ther. 2015;30:16-21.
39. van Ranst D, Stoop WA, Meijer JW, et al. Reduction of exacerbation fre-quency in patients with COPD after participation in a comprehensive pul-monary rehabilitation program. Int J Chron Obstruct Pulmon Dis. 2014; 9:1059-1067.
40. Huertas D, Lopez-Sanchez M, Mateu L, et al. Results of a pulmonary rehabilitation program (PRP) in COPD patients: differences in outcomes according to currently 2011 GOLD groups. Eur Respir J. 2014; 44(Suppl 58):630.
41. Garcia-Rio F, Rojo B, Casitas R, et al. Prognostic value of the objective measurement of daily physical activity in patients with COPD. Chest. 2012;142:338-346.
42. Marin A, Garcia-Aymerich J, Sauleda J, et al; PAC-COPD Study Group. Effect of bronchial colonisation on airway and systemic inflammation in stable COPD. COPD. 2012;9:121-130.
43. Martinez-Garcia MA, de la Rosa Carrillo D, Soler-Cataluna JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013; 187:823-831.
44. Smith IE, Jurriaans E, Diederich S, et al. Chronic sputum production: correlations between clinical features and findings on high resolution computed tomographic scanning of the chest. Thorax. 1996;51: 914-918.
45. Vendrell M, de Gracia J, Olveira C, et al. Diagnostico y tratamiento de las bronquiectasias [Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery]. Arch Bronconeumol. 2008; 44:629-640. Spanish.
46. Renom F, Yanez A, Garau M, et al. Prognosis of COPD patients requiring frequent hospitalization: role of airway infection. Respir Med. 2010;104:840-848.
47. Almagro P, Salvado M, Garcia-Vidal C, et al. Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease. Respiration. 2012;84:36-3.
48. Miravitlles M, Monso E, Mensa J, et al. Antimicrobial treatment of exacerbation in chronic obstructive pulmonary disease: 2007 consensus statement. Arch Bronconeumol. 2008;44:100-108.
49. Gallego M, Pomares X, Espasa M, et al. Pseudomonas aeruginosa iso-lates in severe chronic obstructive pulmonary disease: characterization and risk factors. BMC Pulm Med. 2014;14:103.
50. Murphy TF, Brauer AL, Eschberger K, et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177:853-860.
51. Millares L, Ferrari R, Gallego M, et al. Bronchial microbiome of severe COPD patients colonised by Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2014;33:1101-1111.
52. Dal Negro R, Micheletto C, Tognella S, et al. Tobramycin nebulizer solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation. Adv Ther. 2008;25:1019-1030.
53. Manuel MJ, Munoz-Ezquerre M, Lopez-Sanchez M, et al. Adherencia y efectividad en el control de exacerbaciones en pacientes con EPOC grave bajo el tratamiento con colimicina inhalada (Promixin®) en dis- positivo I-neb [Effectiveness and adherence of inhaled colymycin in I-neb device (Promixin®) for control of exacerbations in severe COPD patients]. Arch Bronconeumol. In: 46th National Congress Spanish Society of Pulmonology and Thoracic Surgery; 2012. Spanish.
54. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, et al. Pneu-monia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med. 2009;361:680-689.
55. Miravitlles M, Soler-Cataluna JJ, Calle M, et al. Spanish guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol. 2014; 50(Suppl 1):1-16.
56. Gomez J, Banos V, Simarro E, et al. Estudio prospectivo y comparativo (1994-1998) sobre la influencia del tratamiento corto profilactico con azitromicina en pacientes con EPOC evolucionada [Prospective, com-parative study (1994-1998) of the influence of short-term prophylactic treatment with azithromycin on patients with advanced COPD]. Rev Esp Quimioterap. 2000;13:379-383. Spanish.
57. Suzuki T, Yanai M, Yamaya M, et al. Erythromycin and common cold in COPD. Chest. 2001;120:730-733.
58. Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178: 1139-1147.
59. Pomares X, Monton C, Espasa M, et al. Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations. Int J Chron Obstruct Pulmon Dis. 2011;6:449-456.
60. He ZY, Ou LM, Zhang JQ, et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration. 2010; 80:445-452.
61. Blasi F, Bonardi D, Aliberti S, et al. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Phamacol Ther. 2010;23:200-207.
62. Allegra L, Blasi F, Diano P, et al. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. Respir Med. 2005;99:742-747.
63. Eller J, Ede A, Schaberg T, et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest. 1998;113:1542-1548.
64. Lode H, Allewelt M, Balk S, et al. A prediction model for bacterial eti-ology in acute exacerbations of COPD. Infection. 2007;35:143-149.
65. Monso E, Garcia-Aymerich J, Soler N, et al. Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect. 2003;131:799-804.
66. Garcia-Vidal C, Almagro P, Romani V, et al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study. Eur Respir J. 2009;34:1072-1078.